Interaction of valproic acid and amitriptyline: Analysis of therapeutic drug monitoring data under naturalistic conditions

Journal of Clinical Psychopharmacology

Volumn 33, Issue 4, 2013, Pages 561-564

  Unterecker, Stefan ^a   Burger, Rainer ^a   Hohage, Amelie ^a   Deckert, Jürgen ^a   Pfuhlmann, Bruno ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

amitriptyline; interaction; valproic acid

Indexed keywords

AMITRIPTYLINE; NORTRIPTYLINE; VALPROIC ACID;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DELIRIUM; DRUG BLOOD LEVEL; DRUG INDUCED DISEASE; DRUG MONITORING; FEMALE; HUMAN; MAJOR DEPRESSION; MALE; PRIORITY JOURNAL; QUALITY CONTROL; RETROSPECTIVE STUDY;

ADULT; AGED; AMITRIPTYLINE; ANTIDEPRESSIVE AGENTS; CHI-SQUARE DISTRIBUTION; DELIRIUM; DEPRESSIVE DISORDER, TREATMENT-RESISTANT; DRUG DOSAGE CALCULATIONS; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VALPROIC ACID; YOUNG ADULT;

EID: 84879839815     PISSN: 02710749     EISSN: 1533712X     Source Type: Journal    
DOI: 10.1097/JCP.0b013e3182905d42     Document Type: Article

References (37)

1. Mishra S, Bhatnagar S, Goyal GN, et al. A comparative efficacy of amitriptyline, gabapentin, and pregabalin in neuropathic cancer pain: a prospective randomized double-blind placebo-controlled study. Am J Hosp Palliat Care. 2012;29:177-182.
2. Smitherman TA, Walters AB, Maizels M, et al. The use of antidepressants for headache prophylaxis. CNS Neurosci Ther. 2011;17:462-469.
3. Stephen LJ. Drug treatment of epilepsy in elderly people: focus on valproic acid. Drugs Aging. 2003;20:141-152.
4. Angalakuditi M, Angalakuditi N. A comprehensive review of the literature on epilepsy in selected countries in emerging markets. Neuropsychiatr Dis Treat. 2011;7:585-597.
5. Wasterlain CG, Baldwin R, Naylor DE, et al. Rational polytherapy in the treatment of acute seizures and status epilepticus. Epilepsia. 2011;52:70-71.
6. Dietrich DE, Emrich HM. The use of anticonvulsants to augment antidepressant medication. J Clin Psychiatry. 1998;59:51-58.
7. Stoffers J, Völlm BA, Rücker G, et al. Pharmacological interventions for borderline personality disorder. Cochrane Database Syst Rev. 2010;16:CD005653.
8. Bisdorff AR. Management of vestibular migraine. Ther Adv Neurol Disord. 2011;4:183-191.
9. Bril V, England JD, Franklin GM, et al. Evidence-based guideline: treatment of painful diabetic neuropathyVreport of the American Association of Neuromuscular and Electrodiagnostic Medicine, the American Academy of Neurology, and the American Academy of Physical Medicine & Rehabilitation. Muscle Nerve. 2011;43:910-917.
10. Pierangeli G, Cevoli S, Sancisi E, et al. Which therapy for which patient? Neurol Sci. 2006;27:S153-158.
11. Couch JR. Update on chronic daily headache. Curr Treat Options Neurol. 2011;13:41-55.
12. Koszewska I, Rybakowski JK. Antidepressant-induced mood conversions in bipolar disorder: a retrospective study of tricyclic versus non-tricyclic antidepressant drugs. Neuropsychobiology. 2009;59:12-16.
13. Bowden CL. Valproate. Bipolar Disord. 2003;5:189-202.
14. Miller JM, Kustra RP, Vuong A, et al. Depressive symptoms in epilepsy: prevalence, impact, aetiology, biological correlates and effect of treatment with antiepileptic drugs. Drugs. 2008;68:1493-1509.
15. Avoni P, Riva R, Albani F. Recurrence of absence seizures induced by a low dose of amitriptyline: a case report. Eur J Neurol. 1996;3:272-274.
16. Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011. Pharmacopsychiatry. 2011;44:195-235.
17. Perucca E. Clinically relevant drug interactions with antiepileptic drugs. Br J Clin Pharmacol. 2005;61:246-255.
18. Patsalos PN, Perucca E. Clinically important drug interactions in epilepsy: interactions between antiepileptic drugs and other drugs. Lancet Neurol. 2003;2:473-481.
19. Spina E, Perucca E. Clinical significance of pharmacokinetic interactions between antiepileptic and psychotropic drugs. Epilepsia. 2002;43:37-44.
20. Wong SL, Cavanaugh J, Shi H, et al. Effects of divalproex sodium on amitriptyline and nortriptyline pharmacokinetics. Clin Pharmacol Ther. 1996;60:48-53.
21. Vandel S, Bertschy G, Jounet JM, et al. Valpromide increases the plasma concentrations of amitriptyline and its metabolite nortriptyline in depressive patients. Ther Drug Monit. 1988;10:386-389.
22. Fu C, Katzman M, Goldbloom DS. Valproate/nortriptyline interaction. J Clin Psychopharmacol. 1994;14:205-206.
23. Gupta SK, Shah JC, Hwang SS. Pharmacokinetic and pharmacodynamic characterizations of OROS\ and immediate-release amitriptyline. J Clin Pharmacol. 1999;48:71-78.
24. Vasudev K, Das S, Goswami U, et al. Pharmacokinetics of valproic acid in patients with bipolar disorder. J Psychopharmacol. 2001;15:187-190.
25. Pfuhlmann B, Gerlach M, Burger R, et al. Therapeutic drug monitoring of tricyclic antidepressants in everyday clinical practice. J Neural Transm Suppl. 2007;72:287-296.
26. Roberts-Thomson KC, Teo KS, Young GD. Drug-induced Brugada syndrome with ST-T wave alternans and long QT. Intern Med J. 2007;37:199-200.
27. DeToledo JC, Haddad H, Ramsay RE. Status epilepticus associated with the combination of valproic acid and clomipramine. Ther Drug Monit. 1997;19:71-73.
28. Fehr C, Gründer G, Hiemke C, et al. Increase of serum clomipramine concentrations caused by valproate. J Clin Psychopharmacol. 2000;20:493-494.
29. Thieme D, Rolf B, Sachs H, et al. Correlation of inter-individual variations of amitriptyline metabolism examined in hairs with CYP2C19 and CYP2D6 polymorphisms. Int J Legal Med. 2008;122:149-155.
30. Schmider J, Greenblatt DJ, Harmatz JS, et al. Enzyme kinetic modelling as a tool to analyse the behaviour of cytochrome P450 catalysed reactions: application to amitriptyline N-demethylation. Br J Clin Pharmacol. 1996;41:593-604.
31. Ghahramani P, Ellis SW, Lennard MS, et al. Cytochromes P450 mediating the N-demethylation of amitriptyline. Br J Clin Pharmacol. 1997;43:137-144.
32. Venkatakrishnan K, Schmider J, Harmatz JS, et al. Relative contribution of CYP3A to amitriptyline clearance in humans: in vitro and in vivo studies. J Clin Pharmacol. 2001;41:1043-1054.
33. Venkatakrishnan K, von Moltke LL, Greenblatt DJ. Application of the relative activity factor approach in scaling from heterologously expressed cytochromes P450 to human liver microsomes: studies on amitriptyline as a model substrate. J Pharmacol Exp Ther. 2001;297:326-337.
34. Venkatakrishnan K, Greenblatt DJ, von Moltke LL, et al. Five distinct human cytochromes mediate amitriptyline N-demethylation in vitro: dominance of CYP 2C19 and 3A4. J Clin Pharmacol. 1998;38:112-121.
35. Breyer-Pfaff U. The metabolic fate of amitriptyline, nortriptyline and amitriptylinoxide in man. Drug Metab Rev. 2004;36:723-746.
36. Wen X, Wang JS, Kivistö KT, et al. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol. 2001;52:547-553.
37. Reis M, Aamo T, Spigset O, et al. Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit. 2009;31:42-56.